skip to Main Content

Welcome

Celebrating 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

ADVOCACY UPDATES

CY 2022 Physician Fee Schedule Proposed Rule Summary

On July 13, the Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician…

read more

Congress Considers Extension of Telehealth Flexibilities Post-Pandemic

The COVID-19 pandemic forced Congress and the Centers for Medicare & Medicaid Services (CMS) to…

read more

Changes To E/M Codes Beginning On January 1st

Effective January 1, 2021, the Centers for Medicare & Medicaid (CMS) finalized significant changes to…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

12/01/21: Research Grant Cycle
Learn more

02/22/22: Deadline For Call For Proposals
Learn more

04/01/22: Fellow Exam Application Deadline
Learn more

06/01/22: Research Grant Cycle
Learn more

06/26/22: Membership Application Deadline to be eligible for AAOA Member rate for the 2022 Basic Course

08/01/22: Scientific Abstract Submission Deadline

09/01/22: Membership Application Deadline to be voted in at the 2022 Annual Meeting

EDUCATION

The live stream of the 2021 AAOA Annual Meeting concluded on October 21st, but you can still register and earn CME/MOC credits. 4 hours of Pre-Work On-Demand content will be accessible until November 15, 2021. If you missed a lecture during our live-streamed content, do not worry. Most of the lectures will be available within the next week until November 15, 2021. Learn More

IFAR

Available Now

IFAR Impact Factor: 2.454

aaoaf-ifar

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2022 AAOA Advanced Course
Hybrid! Santa Fe, NM & Virtually
January 13-15, 2022
Learn More and Register

2022 AAOA Basic Course
The Diptomat Beach Resort, Hollywood, FL
June 30-July 2, 2022

2022 AAOA Annual Meeting
Loews Philadelphia, PA
September 9-11, 2022

USP 797 Online Module
Learn More and Register

News and Updates

DosedDaily: A Free Resource For Residents

The AAOA has partnered with DosedDaily to offer a free resource for residents to support…

read more

OSHA COVID-19 Vaccination & Testing Emergency Temporary Standard

On Friday, November 5, the Occupational Safety and Health Administration (OSHA) issued an interim final…

read more
College Allergy Symptoms Treatment Back to Shcool

PRACTICE RESOURCES

AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More

PARTNER RESOURCE CENTER

AAOA has launched a Partner Resource Center to bring you partner resources that can assist your practice and patient care.

Visit the New Center>

PATIENT CORNER

AAOA Logo

Practice Resources

Compounding Updates

vials of allergens

As we continue to monitor activity both at the FDA and USP in relation to physician compounding, we wanted to offer the latest update.

USP: To provide a unified approach to quality compounding, USP is aligning the timing and content of General Chapters <795>, <797>, and <800>. Chapter <797> Pharmaceutical Compounding – Sterile Preparations is the chapter relating to allergy immunotherapy. Below is the current proposed timeline and web links for use during the public comment periods. AAOA will continue to monitor the progress and alert you when the revised version of <797> is released for comment.

Schedule & Links for Compounding Standards

Click the links for access where the respective information will be posted (Active after 2/28/2018)

 

 

 

<795>*

Pharmaceutical Compounding‒ Nonsterile Preparations

<797>*

Pharmaceutical Compounding Sterile Preparations

Pre-Posted on the USP Website for Public Comment**

 

 March 30, 2018 July 28, 2018
Published in the Pharmacopeial Forum

 

 May 1, 2018 September 4, 2018
Open Microphone Session

Registration will open

 April 20, 2018

 

 March 15, 2018

 

September 5, 2018

 

 August 5, 2018

 

Public Comment Period will close

 

 July 31, 2018

 

November 30, 2018
Intended Publication DateUSP – NF

 

 June 1, 2019

 

June 1, 2019
Anticipated Official Date

 

 December 1, 2019 December 1, 2019

*   The current published versions of USP-NF General Chapters <795> and <797> are official until new chapters become official.

** This pre-posting allows extra time, beyond the typical 90 day period, for stakeholders to review and provide input.

FDA: This morning the FDA held a stakeholder teleconference regarding its final guidance on compounded drug products.  The links below provide the summaries. FDA recognizes that compounded drugs play an important healthcare role for certain patients for whom FDA-approved drugs are not available, as well as the increased risk associated with compounding. As such, this guidance is intended to help reduce that risk.

The final guidance documents that we will discuss are:

Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510154.pdf

Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM510153.pdf

For additional information please visit FDA’s website: https://www.fda.gov/drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/

FDA Approval Updates

The U.S. Food and Drug Administration (FDA) recently approved the following sublingual tablets for pollen-induced allergies:

Merck’s RAGWITEK(TM), a sublingual immunotherapy tablet for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen specific IgE antibodies for short ragweed pollen. The complete press release from Merck is available:RAGWITEK.

Greer’s ORALAIR(R), a sublingual immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen specific IgE antibodies for any of the five grass species contained in the product (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass). The complete press release from Greer is available:ORALAIR.

Merck’s GRASTEK(R), a sublingual immunotherapy tablet for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen specific IgE antibodies for Timothy Grass or cross-reactive grass pollens. The complete press release from Merck is available:<a “href=”https://www.aaoallergy.org/wp-content/uploads/2017/05/GRASTEK-press-release.pdf”>GRASTEK.

A Member Benefit

Allergy and Rhinology Journal (IFAR)

The International Forum of Allergy & Rhinology (IFAR) is the official journal of the AAOA and the American Rhinologic Society (ARS). Published monthly by John Wiley & Sons, Inc., IFAR provides a forum for clinical researchers, basic scientists, clinicians, and others to publish original research and explore controversies in the medical and surgical treatment of patients with otolaryngic allergy, rhinologic, and skull base conditions.

News

New Articles from IFAR

Medical therapy for Chronic Rhino-sinusitis

The indications for surgical management of chronic rhinosinusitis (CRS) in patients with cystic fibrosis (CF) are poorly defined..
Read More

Safety of long-term Intranasal Budesonide

The aim of this study was to determine the impact of long-term topical budesonide treatment via the mucosal atomization device (MAD) on the hypothalamic-pituitary-adrenal axis (HPAA) and intraocular pressure (IOP).. Read More

President Mims Message

April 2017

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices. Read More

Back To Top